比阿培南延长输注治疗重症肺炎的疗效与药物经济学评价

Efficacy and Pharmacoeconomic Evaluation of Biapenem Infusion in Treatment of Severe Pneumonia

目的评价比阿培南延长输注治疗重症肺炎的临床疗效及其药物经济学分析。方法选取本院收治的72例重症肺炎患者,根据比阿培南输注的时间分为两组,各36例。A组采用0.5 h短时间输注,B组采用3 h延长输注,比较两组治疗疗效及药物经济学价值。结果 A、B两组平均治疗时间比较差异无统计学意义(P>0.05);B组的治疗成本显著低于A组(P<0.05);A组不良反应发生率、总有效率、清除率分别为5.56%、83.33%、65.51%,与B组8.33%、88.57%、62.96%比较,差异无统计学意义(P>0.05)。结论比阿培南3 h延长输注治疗重症肺炎的临床疗效确切,且药物经济学较优。

Objective To evaluate the clinical efficacy and pharmacoeconomic analysis of prolonged infusion of biapenem in the treatment of severe pneumonia. Methods Seventy-two patients with severe pneumonia admitted to our hospital were divided into groups according to the infusion time of biapenem,36 patients who were infused for a short time of 0.5 h were used as group A,and 36 patients who were infused for 3 h were used as group B. The therapeutic efficacy and pharmacoeconomic value of the two groups were compared. Results There was no significant difference in mean treatment time between A and B groups(P>0.05).The cost of treatment in group B was significantly lower than that in group A(P<0.05). The adverse reaction rate,total effective rate and clearance rate in group A were 5.56%,83.33% and 65.51%,respectively. There was no significant difference between group A and group B,compared with group B,8.33%,88.57% and 62.96%(P>0.05). Conclusion Biapenem 3 h prolonged infusion is effective in the treatment of severe pneumonia,and the pharmacoeconomics value is better.